{
  "meta": {
    "title": "89_Hemolytic_Anemia",
    "url": "https://brainandscalpel.vercel.app/89-hemolytic-anemia-cf48e8f2.html",
    "scrapedAt": "2025-11-30T12:29:15.652Z"
  },
  "questions": [
    {
      "text": "Which of the following will be seen in a patient with intravascular hemolytic anemia?<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>MCV &nbsp; &nbsp;</strong></td>\n<td><strong>Haptoglobin &nbsp;</strong></td>\n<td><strong>LDH &nbsp; &nbsp; &nbsp;</strong></td>\n<td><strong>Urinary urobilinogen</strong></td>\n</tr>\n<tr>\n<td>1.&nbsp;</td>\n<td>High &nbsp;</td>\n<td>Low &nbsp;</td>\n<td>Low &nbsp;</td>\n<td>Low &nbsp;</td>\n</tr>\n<tr>\n<td>2.&nbsp;</td>\n<td>High &nbsp;</td>\n<td>Low &nbsp;</td>\n<td>High &nbsp;</td>\n<td>High &nbsp;</td>\n</tr>\n<tr>\n<td>3.&nbsp;</td>\n<td>Low &nbsp;</td>\n<td>High &nbsp;</td>\n<td>Low &nbsp;</td>\n<td>Low &nbsp;</td>\n</tr>\n<tr>\n<td>4.&nbsp;</td>\n<td>Low &nbsp;</td>\n<td>High &nbsp;</td>\n<td>High &nbsp;</td>\n<td>High &nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div>",
      "choices": [
        {
          "id": 1,
          "text": "1"
        },
        {
          "id": 2,
          "text": "2"
        },
        {
          "id": 3,
          "text": "3"
        },
        {
          "id": 4,
          "text": "4"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>In <strong>intravascular hemolysis</strong>, there is elevated MCV, LDH, and urinary urobilinogen, with low haptoglobin.</p>\n<p>Laboratory abnormalities seen in intravascular hemolysis:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Lab parameters</strong></td>\n<td><strong>Derangement</strong></td>\n<td><strong>Mechanism</strong></td>\n</tr>\n<tr>\n<td>MCV</td>\n<td>High</td>\n<td>Compensatory reticulocytosis</td>\n</tr>\n<tr>\n<td>S. LDH</td>\n<td>High</td>\n<td>Released from RBCs</td>\n</tr>\n<tr>\n<td>S. Unconjugated bilirubin</td>\n<td>High</td>\n<td>Hemoglobin from RBCs is converted to bilirubin</td>\n</tr>\n<tr>\n<td>Urinary urobilinogen</td>\n<td>High</td>\n<td>Unconjugated bilirubin is excreted as urobilinogen in urine</td>\n</tr>\n<tr>\n<td>S. Haptoglobin</td>\n<td>Low</td>\n<td>Free hemoglobin in circulation binds to haptoglobin causing reduced haptoglobin levels</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Additionally, hemoglobinuria and hemosiderinemia may be seen on urine examination.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4335",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not due to an extracorpuscular defect in RBCs?",
      "choices": [
        {
          "id": 1,
          "text": "Autoimmune hemolytic anemia"
        },
        {
          "id": 2,
          "text": "Paroxysmal nocturnal hemoglobinuria"
        },
        {
          "id": 3,
          "text": "Familial hemolytic uremic syndrome"
        },
        {
          "id": 4,
          "text": "Microangiopathic hemolytic anemia"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Paroxysmal nocturnal hemoglobinuria (<strong>PNH</strong>) is a hemolytic anemia due to an&nbsp;<strong>intracorpuscular</strong> defect.</p>\n<p>It is caused due to&nbsp;an acquired somatic mutation leading to <strong>deficiency</strong> of membrane protective factors <strong>CD59 </strong>and<strong> CD55</strong>. This makes the RBC extremely sensitive to complement activation and causes <strong>intravascular hemolysis</strong>.&nbsp;</p>\n<p>The other conditions occur due to extracorpuscular defects.</p>\n<p>Option A: In autoimmune hemolytic anemia, RBCs are coated with autoantibodies. This triggers&nbsp;phagocytosis in the reticuloendothelial system leading to extravascular hemolysis.&nbsp;&nbsp;</p>\n<p>Option C: Familial hemolytic uremic syndrome (atypical HUS) is an inherited abnormality with excessive complement activation leading to episodic and excessive production of membrane attack complex destroying normal RBCs.</p>\n<p>Option D: Microangiopathic hemolytic anemia is non-immune hemolysis&nbsp;resulting from intravascular red blood cell fragmentation due to abnormalities in the microvasculature.&nbsp;</p><hr><h3>Related Pearl: Classification of Hemolytic Anemias</h3><p>Hemolytic anemias can be classified in 2 ways:</p>\n<p>1. Based on the <strong>type of defect</strong>:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type </strong></td>\n<td><strong>Intracorpuscular Defects</strong></td>\n<td><strong>Extracorpuscular Factors</strong></td>\n</tr>\n<tr>\n<td>Hereditary</td>\n<td>\n<p>Hemoglobinopathies</p>\n<p>Enzymopathies</p>\n<p>Membrane-cytoskeletal defects</p>\n</td>\n<td>Familial (atypical) hemolytic uremic syndrome</td>\n</tr>\n<tr>\n<td>Acquired</td>\n<td>Paroxysmal nocturnal hemoglobinuria (PNH)</td>\n<td>\n<p>Mechanical destruction (microangiopathic)</p>\n<p>Toxic agents</p>\n<p>Drugs</p>\n<p>Infectious</p>\n<p>Autoimmune</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>2. Based on the <strong>sites</strong> of <strong>hemolysis:</strong></p>\n<p><strong>Intravascular </strong>hemolysis<strong>:</strong></p>\n<ul>\n<li><span class=\"TextRun SCXW225898103\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW225898103\">Mechanical injury</span></span>\n<ul>\n<li data-leveltext=\"%1.\" data-font=\"Calibri, sans-serif\" data-listid=\"2\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\">Trauma caused by cardiac valves </li>\n<li data-leveltext=\"%1.\" data-font=\"\" data-listid=\"2\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\">Microangiopathic hemolytic anaemias (hemolytic uremic syndrome, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura) </li>\n<li data-leveltext=\"%1.\" data-font=\"\" data-listid=\"2\" aria-setsize=\"-1\" data-aria-posinset=\"3\" data-aria-level=\"1\">Repetitive physical trauma</li>\n</ul>\n</li>\n<li><span class=\"TextRun SCXW46333709\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW46333709\">Complement fixation (antibody-mediated destruction)</span></span>\n<ul>\n<li data-leveltext=\"%1.\" data-font=\"Calibri, sans-serif\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\">Hemolytic disease of the newborn- ABO incompatibility </li>\n<li data-leveltext=\"%1.\" data-font=\"Calibri, sans-serif\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\">Transfusion reaction  </li>\n<li data-leveltext=\"%1.\" data-font=\"\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"4\" data-aria-level=\"1\">Drug-induced </li>\n</ul>\n</li>\n<li><span class=\"TextRun SCXW127641793\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW127641793\">Infections of red blood cells </span></span>\n<ul>\n<li><span class=\"TextRun SCXW127641793\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW127641793\">Malaria</span></span></li>\n<li><span class=\"TextRun SCXW127641793\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW127641793\">B</span></span><span class=\"TextRun SCXW127641793\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"SpellingError SCXW127641793\">abesiosis</span></span></li>\n</ul>\n</li>\n<li><span class=\"EOP SCXW127641793\" data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\"><span class=\"TextRun SCXW261552469\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW261552469\">Exogenous toxic factors - c</span></span></span><span class=\"EOP SCXW127641793\" data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\"><span class=\"TextRun SCXW261552469\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"SpellingError SCXW261552469\">lostridial</span></span><span class=\"TextRun SCXW261552469\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW261552469\"> sepsis</span></span></span></li>\n</ul>\n<div class=\"ng-scope\">\n<div class=\"ng-scope\">\n<p class=\"ng-binding\"><strong>Extravascular </strong>hemolysis<strong>:</strong></p>\n<ul>\n<li>Hereditary spherocytosis</li>\n<li>Thalassemia</li>\n<li>Sickle cell anemia</li>\n<li>Hemolytic disease of the newborn- Rh incompatibility</li>\n</ul>\n<p><strong>Both</strong> intravascular and extravascular hemolysis:</p>\n<ul>\n<li>G6PD deficiency</li>\n<li>Autoimmune hemolytic anemia</li>\n</ul>\n</div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4338",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is true about paroxysmal nocturnal hemoglobinuria?",
      "choices": [
        {
          "id": 1,
          "text": "Inherited defect in PIG –A"
        },
        {
          "id": 2,
          "text": "Extravascular hemolysis"
        },
        {
          "id": 3,
          "text": "Deficiency of CD 55 and CD 59"
        },
        {
          "id": 4,
          "text": "Microcytic anaemia"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Deficiency of <strong>CD55</strong> and <strong>CD59</strong> is seen in <strong>paroxysmal nocturnal hemoglobinuria</strong> (PNH).</p>\n<p>It is due to an <strong>acquired mutation</strong> in the <strong>X-linked</strong> phosphatidylinositol class A <strong>PIG-A gene</strong> (Option A) causing a <strong>deficiency</strong> of <strong>GPI anchor proteins</strong>. GPI is a glycolipid that <strong>anchors membrane protective factors</strong> such as CD59 and CD55 to the membrane. The deficiency of CD55 and CD59 makes the <strong>RBC </strong>sensitive to <strong>complement-mediated intravascular hemolysis</strong>(Option B). The <strong>anemia</strong> is usually <strong>normo-macrocytic</strong> (Option D).</p>\n<p><strong>Hemolysis</strong> tends to occur at <strong>night</strong> due to a slight <strong>decrease in blood pH</strong> during sleep, which triggers complement activity (nocturnal hemoglobinuria). <strong>PNH</strong> is characterized by <strong>hemolytic anemia</strong>, <strong>pancytopenia</strong>, and <strong>venous thrombosis</strong>.</p>\n<p>PNH is diagnosed using <strong>flow cytometry</strong>. The drugs of choice for treatment are <strong>Eculizumab</strong> or <strong>Ravulizumab</strong> which work against <strong>complement C5</strong>. Supportive management of PNH includes <strong>folic acid</strong> and <strong>iron supplementation</strong>. Bone marrow transplantation is another option for the treatment of this condition. </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4364",
      "difficulty": "medium"
    },
    {
      "text": "A patient with hemolytic anemia develops features of pancytopenia and venous thrombosis. What is the likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Shwachman-Diamond syndrome"
        },
        {
          "id": 2,
          "text": "Pyruvate kinase deficiency"
        },
        {
          "id": 3,
          "text": "G6PD anemia"
        },
        {
          "id": 4,
          "text": "Paroxysmal nocturnal hemoglobinuria"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Paroxysmal nocturnal hemoglobinuria <strong>(PNH) </strong>is a type of <strong>hemolytic anemia</strong> associated with <strong>pancytopenia </strong>and<strong> venous thrombosis</strong>.</p>\n<p>In PNH, there is complement-mediated intravascular hemolysis. Bone marrow dysfunction also occurs, resulting in pancytopenia. Transformation to <strong>aplastic anemia</strong> or acute myeloid leukemia (<strong>AML</strong>) may rarely occur. </p>\n<p>PNH is also associated with venous thrombosis (cerebral, renal, hepatic).<strong> </strong>This is the most common cause of death in PNH. </p>\n<p>Option A: Shwachman-Diamond syndrome is inherited aplastic anemia with neutropenia with pancreatic insufficiency and malabsorption.</p>\n<p>Options B and C: Pyruvate kinase and G6PD deficiency are inherited RBC enzyme disorders causing extravascular hemolytic anemias. They do not affect other cell lines and are not associated with venous thrombosis.</p>\n<p> </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4363",
      "difficulty": "easy"
    },
    {
      "text": "A 31-year-old woman presents with a fever and cough. She also reports excessive tiredness and occasional dark-colored urine for the past 6 months. Chest X-ray reveals lower lobe pneumonia. Labs reveal the following. What is the investigation of choice for this condition?<div class='question-desc-html'><p>Hb - 7.6 g/dL</p>\n<p>RBC - 2 million/mm<sup>3</sup></p>\n<p>WBC - 5,000/mm<sup>3</sup></p>\n<p>Platelets - 100,000/mm<sup>3</sup>&nbsp;</p>\n<p>Reticulocyte count - 3.2%</p>\n<p>S. LDH - High</p>\n<p>S. Haptoglobin - Low</p>\n<p>Coombs test - negative</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Acidified serum / HAM test"
        },
        {
          "id": 2,
          "text": "Eosin-5′-maleimide-binding test"
        },
        {
          "id": 3,
          "text": "Flow cytometry"
        },
        {
          "id": 4,
          "text": "Acidified glycerol lysis test"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>This clinical scenario is suggestive of <strong>intravascular hemolysis</strong> due to paroxysmal nocturnal hemoglobinuria (<strong>PNH</strong>). The gold standard for diagnosis is&nbsp;<strong>flow cytometry</strong>.</p>\n<p>Flow cytometry is performed with fluorescently labeled monoclonal antibodies that bind to GPI-anchored proteins (CD59, CD55). Most tests also use&nbsp;<strong>FL</strong>uorescent <strong>AER</strong>olysin (<strong>FLAER</strong>), a reagent that directly binds the GPI anchor. <strong>Absence </strong>of&nbsp;<strong>CD59</strong> and <strong>CD55</strong>&nbsp;are diagnostic of PNH.&nbsp;</p>\n<p>Other investigations in PNH include:</p>\n<ul>\n<li><strong>Ham test</strong>&nbsp;(acidified serum lysis) - lysis of RBCs in a mildly acidic pH due to complement fixation.&nbsp;</li>\n<li><strong>Bone marrow biopsy</strong>:\n<ul>\n<li>Hypercellularity with erythroid hyperplasia is seen in classical presentations.</li>\n<li>Patients who develop pancytopenia will have hypocellular bone marrow. &nbsp;</li>\n</ul>\n</li>\n<li>Imaging - to evaluate venous thrombosis.</li>\n</ul>\n<p>Option B and D:&nbsp;Eosin-5&prime;-maleimide-binding and acidified glycerol lysis tests&nbsp;are done in hereditary spherocytosis.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4366",
      "difficulty": "easy"
    },
    {
      "text": "A 46-year-old woman presents with abdominal pain and yellowish discoloration of her skin. She gives a history of dark-colored urine which is more pronounced in the early mornings. Imaging reveals hepatic venous thrombosis. Flow cytometry reveals the absence of GPI-anchored proteins. What is the drug of choice?",
      "choices": [
        {
          "id": 1,
          "text": "Rituximab"
        },
        {
          "id": 2,
          "text": "Certolizumab"
        },
        {
          "id": 3,
          "text": "Eculizumab"
        },
        {
          "id": 4,
          "text": "Alemtezumab"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>This clinical scenario is suggestive of paroxysmal nocturnal hemoglobinuria (<strong>PNH</strong>). C5 complement inhibitors like <strong>eculizumab</strong>&nbsp;and <strong>ravalizumab</strong> are the drugs of choice in PNH.&nbsp;</p>\n<p>Management of PNH involves the following:</p>\n<ul>\n<li><strong>C5 complement inhibitors&nbsp;</strong>prevent the formation of membrane attack complex and complement-mediated lysis.</li>\n<li><strong>Bone marrow transplant</strong>&nbsp;is useful for patients with severe pancytopenia</li>\n<li>Supportive measures:\n<ul>\n<li>Transfusion of filtered RBCs</li>\n<li>Folic acid, and iron supplementation</li>\n<li>Anticoagulants in case of venous thrombosis&nbsp;</li>\n</ul>\n</li>\n</ul><p>The&nbsp;FDA has recently approved pegcetacoplan for adults with PNH which acts by binding to complement protein C3 and increasing hemoglobin concentration.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4367",
      "difficulty": "easy"
    },
    {
      "text": "A 10-year-old boy is brought for evaluation of fatigue. On examination, he is jaundiced and mild splenomegaly is noted. He was adopted and his family history is unknown. Peripheral smear findings are shown below. What is the most specific investigation for this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Eosin-5-maleimide test"
        },
        {
          "id": 2,
          "text": "Acidified glycerol lysis test"
        },
        {
          "id": 3,
          "text": "Osmotic fragility test"
        },
        {
          "id": 4,
          "text": "NESTROFT test"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The peripheral smear shows hyperchromic RBCs with loss of central pallor or spherocytes. These findings are suggestive of <strong>hereditary spherocytosis</strong>. The <strong>eosin-5-maleimide</strong> test is the <strong>most specific</strong> investigation for this condition.&nbsp;</p>\n<p>It is a <strong>flow cytometric test</strong> based on the interaction between the dye eosin-5-maleimide and band 3 protein.</p>\n<p>Other investigations that can be performed in this condition are:</p>\n<p><strong>Acidified glycerol lysis test:</strong> Spherocytes from patients with hereditary spherocytosis lyse more quickly than normal red blood cells when incubated in a phosphate buffered hypotonic solution with added glycerol. It has&nbsp;greater sensitivity and specificity than the osmotic fragility test.</p>\n<p><strong>Osmotic fragility test:</strong>&nbsp;Detects hemolysis by measuring the fraction of total hemoglobin released from red cells when suspended in progressively more dilute salt concentrations.</p>\n<p>Note: NESTROFT (Naked eye single tube red-cell osmotic fragility test) is a highly sensitive test used as a screening test for thalassemia.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/03fa09fb02f940b9aa4e42257af3ee04.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0757",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following is true regarding the treatment of hereditary spherocytosis?",
      "choices": [
        {
          "id": 1,
          "text": "Cholecystectomy is only indicated for patients with clinical cholelithiasis at the time of splenectomy"
        },
        {
          "id": 2,
          "text": "Cholecystectomy cannot be performed via laparoscopic route for patients with HS and pigment gall stones"
        },
        {
          "id": 3,
          "text": "Splenectomy is indicated in patients with mild and asymptomatic disease only after puberty"
        },
        {
          "id": 4,
          "text": "Lifelong penicillin prophylaxis after splenectomy is mandatory for all adult patients"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Cholecystectomy</strong> at the time of splenectomy is indicated in patients with hereditary spherocytosis (HS) only if they have<strong> symptomatic cholelithiasis</strong> at the time of surgery. It is usually carried out via a&nbsp;<strong>laparoscopic</strong>&nbsp;approach.</p>\n<p><strong>Penicillin prophylaxis</strong> after splenectomy is controversial. Routine penicillin prophylaxis is not mandatory for adults. It is recommended&nbsp;up to age of five and for at least one year following splenectomy.</p>\n<p>Guidelines for the timing of <strong>splenectomy</strong> in HS:</p>\n<ul>\n<li>Mild cases&nbsp;-&nbsp;avoid splenectomy.</li>\n<li>Moderate cases&nbsp;- delay until puberty</li>\n<li>Severe cases - at 4&ndash;6 years of age</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4361",
      "difficulty": "medium"
    },
    {
      "text": "The peripheral smear of a patient is given below. What is the most common mutation associated with the hereditary form of this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Spectrin"
        },
        {
          "id": 2,
          "text": "Band 4.2"
        },
        {
          "id": 3,
          "text": "Band 4.1"
        },
        {
          "id": 4,
          "text": "Ankyrin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given peripheral smear shows&nbsp;oval, elongated, rod, or cigar-shaped RBCs suggestive of <strong>elliptocytosis</strong>. The hereditary form is most commonly associated with the <strong>spectrin</strong> genes.</p>\n<p>The following proteins are implicated in <strong>hereditary elliptocytosis</strong> (HE):</p>\n<ul>\n<li>&alpha;-Spectrin (SPTA1 gene) - 65%</li>\n<li>&beta;-Spectrin (SPTB gene) - 30%</li>\n<li>Band 4.1&nbsp;</li>\n</ul>\n<p>The treatment of choice is splenectomy, preferably after 5 years of age.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/f5f168637ef3475cabdb47b10b90886b.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4362",
      "difficulty": "medium"
    },
    {
      "text": "A young couple comes to you for genetic counseling. The husband is a known case of G6PD deficiency and is concerned about passing it on to his future children. What is the chance that his children will inherit the disease?",
      "choices": [
        {
          "id": 1,
          "text": "Only male children will be affected"
        },
        {
          "id": 2,
          "text": "1 in 2 chance"
        },
        {
          "id": 3,
          "text": "Females can inherit the mutation"
        },
        {
          "id": 4,
          "text": "1 in 4 chance"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>G6PD deficiency is an <strong>X-linked recessive</strong> disorder. <strong>Male children</strong> of an affected man are<strong> not affected</strong> as they receive only the paternal Y chromosome. However, the mutation can be passed on to <strong>female</strong> children, who are typically <strong>carriers</strong> of the disease.</p>\n<p>G6PD deficiency is the most common enzymatic disorder of RBCs.&nbsp;G6PD enzyme is involved in the generation of<strong> NADPH</strong> and protects RBCs from <strong>oxidative injury</strong>.<span class=\"headingEndMark\">&nbsp;Hence, patients with</span>&nbsp;G6PD deficiency have episodes of acute hemolysis in the setting of oxidant injury from medications, acute infections, and certain foods (fava beans/broad&nbsp;beans).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4339",
      "difficulty": "medium"
    },
    {
      "text": "A 35-year-old male with chronic bacterial prostatitis was treated with cotrimoxazole.  Within a few days, he developed malaise, jaundice, abdominal pain, and dark urine. The blood picture is given below. What is the likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Hemolytic uremic syndrome"
        },
        {
          "id": 2,
          "text": "Autoimmune hemolytic anemia"
        },
        {
          "id": 3,
          "text": "Paroxysmal nocturnal hemoglobinuria"
        },
        {
          "id": 4,
          "text": "Glucose 6 phosphate dehydrogenase deficiency"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given clinical features are suggestive of an <strong>acute hemolytic </strong>reaction following the administration of cotrimoxazole. This is suggestive of glucose-6-phosphate dehydrogenase (<strong>G6PD</strong>) <strong>deficiency</strong>.</p>\n<p>In G6PD deficiency&nbsp;uncontrolled oxidative stress causes hemoglobin to denature and form Heinz bodies. Removal of Heinz bodies by macrophages in the spleen results in the formation of characteristic <strong>bite cells</strong>&nbsp;or degmacytes or blister cells (as shown in the image).</p>\n<p>A hemolytic attack starts with abrupt onset of malaise, weakness, and abdominal or lumbar pain. After an interval of several hours to 2&ndash;3 days, the patient develops jaundice and often dark urine, due to <strong>hemoglobinuria</strong>.&nbsp;</p>\n<p>Drugs that carry the risk of clinical hemolysis in persons with G6PD deficiency:</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p>Drug groups</p>\n</td>\n<td>\n<p>Examples</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Antimalarials</p>\n</td>\n<td>\n<p>Primaquine</p>\n<p><strong>Chloroquine</strong></p>\n<p>Dapsone/chlorproguanil</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Sulphonamides/</p>\n<p>sulphones</p>\n</td>\n<td>\n<p><strong>Sulfamethoxazole</strong></p>\n<p>Sulfasalazine</p>\n<p>Sulfisoxazole</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Antibacterial/</p>\n<p>antibiotics</p>\n</td>\n<td>\n<p>Cotrimoxazole</p>\n<p>Ciprofloxacin</p>\n<p>Chloramphenicol</p>\n<p>Nalidixic acid</p>\n<p>Norfloxacin</p>\n<p><strong>Nitrofurantoin</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Others</p>\n</td>\n<td>\n<p>Naphthalene</p>\n<p><strong>Methylene blue</strong></p>\n<p>Rasburicase</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Note: Cotrimoxazole contains sulfamethoxazole.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/3834becd3c32423ea85469a923ac8a91.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4343",
      "difficulty": "easy"
    },
    {
      "text": "The peripheral smear of a patient is given below. It is characteristic of which of the following conditions?",
      "choices": [
        {
          "id": 1,
          "text": "Glucose 6 Phosphate dehydrogenase deficiency"
        },
        {
          "id": 2,
          "text": "Pyruvate kinase deficiency"
        },
        {
          "id": 3,
          "text": "5' nucleotidase deficiency"
        },
        {
          "id": 4,
          "text": "Cytochrome b5 reductase deficiency"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The above peripheral smear shows&nbsp;<strong>basophilic stippling</strong>. It is characteristic of&nbsp;<strong>5' nucleotidase deficiency.</strong></p>\n<p>Pyrimidine 5'-nucleotidase (P5'N-1) deficiency is the third most common enzyme abnormality causing <strong>hereditary</strong> <strong>hemolytic anemia</strong>. It is an&nbsp;<strong>autosomal recessive</strong>&nbsp;trait. &nbsp;</p>\n<p>The hallmark of this enzyme deficiency is the presence of pronounced<strong> basophilic stippling </strong>and&nbsp;accumulation of pyrimidine nucleotides&nbsp;<strong>(RNA</strong> <strong>remnants</strong>) within erythrocytes.&nbsp;</p>\n<p><strong>Cabot rings&nbsp;</strong>may also be seen. They&nbsp;are thin, threadlike, red to violet rings or figure-of-8 shaped inclusions in red blood cells. They are remnants of the <strong>mitotic spindle</strong> and are seen in conditions causing dyserythropoiesis.</p>\n<p>Basophilic stippling is also seen in the following conditions:</p>\n<ul>\n<li>Lead toxicity</li>\n<li>Sideroblastic anemia</li>\n<li>Severe thalassemia</li>\n<li>Conditions with impaired cell division</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/d03687414d4f4a9a9b77cff171f60c1f.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4345",
      "difficulty": "hard"
    },
    {
      "text": "A patient with SLE is found to have warm autoimmune hemolytic anemia. Name the antibody and the site of hemolysis in this condition?",
      "choices": [
        {
          "id": 1,
          "text": "IgM and Extavascular hemolysis"
        },
        {
          "id": 2,
          "text": "IgG and extravascular hemolysis"
        },
        {
          "id": 3,
          "text": "IgM and intravascular hemolysis"
        },
        {
          "id": 4,
          "text": "IgG and intravascular hemolysis"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The antibody involved in <strong>warm</strong> autoimmune hemolytic anemia (<strong>AIHA</strong>) is <strong>IgG</strong>, which causes&nbsp;<strong>extravascular</strong> <strong>hemolysis</strong>.</p>\n<p>IgG is called a&nbsp;warm<strong>&nbsp;</strong>antibody, as it binds to target proteins&nbsp;at <strong>37&nbsp;<sup>o</sup>C.&nbsp;</strong>On the other hand,&nbsp;<strong>cold</strong> antibodies or <strong>IgM</strong> are reactive at 4 to 30<sup>o</sup>C.</p>\n<p>In AIHA, autoantibodies against RBC antigens are produced which coat the RBC membrane. The Fc portion of the antibody is recognized by the Fc receptor on macrophages causing <strong>phagocytosis</strong>. RBC destruction takes place in extravascular sites where macrophages are abundant.</p><hr><h3>Related Pearl: Classification of acquired Immune Hemolytic Anemias</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Clinical setting </strong></p>\n</td>\n<td>\n<p><strong>Warm autoimmune hemolysis </strong></p>\n</td>\n<td>\n<p><strong>Cold autoimmune hemolysis</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Antibody (optimal temperature)</p>\n</td>\n<td>\n<p>IgG (37<sup>0</sup> C)</p>\n</td>\n<td>\n<p>IgM (4-30<sup>0</sup>C)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Secondary to viral infection</p>\n</td>\n<td>\n<p>HIV</p>\n<p>Viral vaccines</p>\n</td>\n<td>\n<p>EBV</p>\n<p>CMV</p>\n<p>others</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Secondary to other infection</p>\n</td>\n<td>&nbsp;</td>\n<td>\n<p>Mycoplasma</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Associated with</p>\n</td>\n<td>\n<p>SLE</p>\n<p>Chronic lymphocytic leukemia</p>\n<p>Inflammatory bowel disease</p>\n<p>Post allogenic HSCT</p>\n</td>\n<td>\n<p>Waldenstrom's Disease</p>\n<p>Lymphoma</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Autoimmune Hemolytic Anemia</h3><p>Autoimmune hemolytic anemia (AIHA): A comparison of types</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Warm agglutinin AIHA</strong></td>\n<td><strong>Cold agglutinin AIHA</strong></td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong><strong>Etiology</strong></strong></td>\n</tr>\n<tr>\n<td>\n<p>Drugs (e.g., penicillin)</p>\n<p>Viral infections</p>\n<p>Autoimmune(e.g., SLE)</p>\n<p>Immunodeficiency states</p>\n<p>Lymphoproliferative (e.g., CLL)</p>\n</td>\n<td>\n<p>Infections (e.g., <em>Mycoplasma pneumoniae</em>&nbsp;and EBV)</p>\n<p>Lymphoproliferative diseases</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p><strong>Clinical presen</strong><strong>tation</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Direct Coombs&rsquo; positive with <strong>anti-IgG, anti-C3</strong>, or both</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>Livedo reticularis and acral cyanosis with cold exposure that disappears with warming</p>\n<p>Direct Coombs&rsquo; positive with <strong>anti-C3 </strong>or<strong> anti-IgM</strong>, but usually not IgG.</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p><strong>Complications</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Venous thromboembolism</p>\n<p>Lymphoproliferative disorders</p>\n</td>\n<td>\n<p>Ischemia and peripheral gangrene</p>\n<p>Lymphoproliferative disorders</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>Treatment</strong></td>\n</tr>\n<tr>\n<td>\n<p>Steroids, splenectomy, rituximab</p>\n</td>\n<td>\n<p>Avoid cold exposure, rituximab</p>\n<p>(No role for steroids,&nbsp;splenectomy, or IVIG)</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4356",
      "difficulty": "medium"
    },
    {
      "text": "Patients with which of the following are least likely to develop autoimmune hemolytic anemia?",
      "choices": [
        {
          "id": 1,
          "text": "Infectious mononucleosis"
        },
        {
          "id": 2,
          "text": "Non-Hodgkin's lymphoma"
        },
        {
          "id": 3,
          "text": "Ulcerative colitis"
        },
        {
          "id": 4,
          "text": "Chronic myeloid leukemia"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Autoimmune hemolytic anemia (<strong>AIHA</strong>) is commonly associated with <strong>CLL</strong> (chronic lymphocytic leukemia). It is not a typical feature of CML (chronic myeloid leukemia).</p>\n<p>AIHA can develop secondary to several autoimmune and infectious causes, as well as drugs.<strong>&nbsp;Drug-induced</strong>&nbsp;hemolytic anemia can occur by the following mechanisms:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Mechanism</strong></td>\n<td><strong>Drugs</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Adsorption</strong>:</p>\n<p>Drugs coat the RBC membrane.&nbsp;Antibodies are directed against the membrane&ndash;drug complex</p>\n</td>\n<td>\n<p>Cefotetan</p>\n<p>Ceftriaxone</p>\n<p>Piperacillin</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Innocent bystander:</strong></p>\n<p>Drugs&nbsp;bind to antibodies in the plasma.&nbsp;This immune complex activates the complement system and destroys nearby RBCs (innocent bystanders)</p>\n</td>\n<td>\n<p>Sulfonamides</p>\n<p>Quinine</p>\n<p>Quinidine</p>\n<p>Phenothiazines&nbsp;&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>Some drugs trigger the production of <strong>autoantibodies</strong></td>\n<td>Methyldopa</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Classification of acquired Immune Hemolytic Anemias</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Clinical setting </strong></p>\n</td>\n<td>\n<p><strong>Warm autoimmune hemolysis </strong></p>\n</td>\n<td>\n<p><strong>Cold autoimmune hemolysis</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Antibody (optimal temperature)</p>\n</td>\n<td>\n<p>IgG (37<sup>0</sup> C)</p>\n</td>\n<td>\n<p>IgM (4-30<sup>0</sup>C)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Secondary to viral infection</p>\n</td>\n<td>\n<p>HIV</p>\n<p>Viral vaccines</p>\n</td>\n<td>\n<p>EBV</p>\n<p>CMV</p>\n<p>others</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Secondary to other infection</p>\n</td>\n<td>&nbsp;</td>\n<td>\n<p>Mycoplasma</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Associated with</p>\n</td>\n<td>\n<p>SLE</p>\n<p>Chronic lymphocytic leukemia</p>\n<p>Inflammatory bowel disease</p>\n<p>Post allogenic HSCT</p>\n</td>\n<td>\n<p>Waldenstrom's Disease</p>\n<p>Lymphoma</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4357",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following are associated with a positive Coombs test?<div class='question-desc-html'><ol>\n<li>Paroxysmal cold hemoglobinuria</li>\n<li>Paroxysmal nocturnal hemoglobinuria</li>\n<li>Cold agglutinin disease</li>\n<li>Drug-induced hemolytic anemia</li>\n<li>Hereditary spherocytosis</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 2, 4"
        },
        {
          "id": 2,
          "text": "2, 3, 5"
        },
        {
          "id": 3,
          "text": "2, 4, 5"
        },
        {
          "id": 4,
          "text": "1, 3, 4"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Paroxysmal nocturnal hemoglobinuria (PNH) and hereditary spherocytosis are not Coomb's positive conditions. The following&nbsp;are Coombs-positive hemolytic anemias:</p>\n<ul>\n<li>Autoimmune hemolytic anemia (AIHA)\n<ul>\n<li>Warm AIHA</li>\n<li>Cold agglutinin disease</li>\n</ul>\n</li>\n<li>Paroxysmal cold hemoglobinuria (PCH)</li>\n<li>Drug-induced hemolytic anemia</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/c77092a1cb4d4020ac7fbc6022a783b5x1280x1197.PNG\" alt=\"Explanation Image\"><p>In <strong>PCH,</strong>&nbsp;the <strong>direct&nbsp;</strong>Coomb's test will be <strong>positive</strong> for <strong>complement</strong> only. This condition is characterized by the presence of the <strong>Donath-Landsteiner</strong> antibody. It is a unique antibody with anti-P specificity at 4&deg;C. Hence, it binds to the RBC at 4&deg;C. However, it causes <strong>complement-mediated lysis</strong> at 37&deg;C.</p>\n<p>Interpretation of direct Coomb's test results:</p>\n<table>\n<tbody>\n<tr>\n<td rowspan=\"2\">Condition</td>\n<td colspan=\"2\">Agglutination with</td>\n</tr>\n<tr>\n<td>anti- IgG</td>\n<td>anti- C3</td>\n</tr>\n<tr>\n<td>Warm AIHA</td>\n<td>+</td>\n<td>+</td>\n</tr>\n<tr>\n<td>Drug-induced</td>\n<td>+</td>\n<td>+</td>\n</tr>\n<tr>\n<td>PCH</td>\n<td>-</td>\n<td>+</td>\n</tr>\n<tr>\n<td>Cold agglutinin disease (IgM)</td>\n<td>-</td>\n<td>+</td>\n</tr>\n<tr>\n<td>PNH</td>\n<td>-</td>\n<td>-</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4358",
      "difficulty": "easy"
    },
    {
      "text": "A 20-year-old woman presented with fatigue and intermittent dark-colored urine. Further evaluation revealed positive Donath  Landsteiner antibodies. What is the likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Warm autoimmune hemolytic anemia"
        },
        {
          "id": 2,
          "text": "Cold autoimmune hemolytic anemia"
        },
        {
          "id": 3,
          "text": "Paroxysmal cold hemoglobinuria"
        },
        {
          "id": 4,
          "text": "Paroxysmal nocturnal hemoglobinuria"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Donath Landsteiner</strong> antibody is specific for paroxysmal cold hemoglobinuria (<strong>PCH</strong>). PCH is a rare form of autoimmune hemolytic anemia.</p>\n<p>The mechanism of this antibody includes:</p>\n<ul>\n<li>Binding to RBCs at 4&deg;C</li>\n<li>Complement-mediated lysis at 37&deg;C</li>\n</ul>\n<p>This condition presents with&nbsp;<strong>intravascular hemolysis</strong> and <strong>hemoglobinuria</strong>.&nbsp;Blood transfusion is required in severe anemia. It is a self-limiting condition.</p>\n<p>The differences between PCH and PNH are given below:</p>\n<table>\n<tbody>\n<tr>\n<td>Condition</td>\n<td><strong>Paroxysmal nocturnal hemoglobinuria (PNH)</strong></td>\n<td><strong>Paroxysmal cold hemoglobinuria (PCH)</strong></td>\n</tr>\n<tr>\n<td>Onset</td>\n<td>Chronic with acute exacerbations</td>\n<td>Acute</td>\n</tr>\n<tr>\n<td>Pathogenesis</td>\n<td><strong>Complement-mediated</strong> destruction of CD59/55(&ndash;) RBCs</td>\n<td><strong>Immune lysis</strong> of normal red cells</td>\n</tr>\n<tr>\n<td>Diagnosis</td>\n<td>Flow cytometry to display a CD55/CD59(&ndash;) red cell population</td>\n<td>Test for <strong>Donath-Landsteiner</strong> antibody</td>\n</tr>\n<tr>\n<td>Triggers</td>\n<td>Infections, alcohol, exercise, stress, or&nbsp; medications</td>\n<td>Triggered by viral infection</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4359",
      "difficulty": "medium"
    },
    {
      "text": "Microangiopathic hemolytic anemia is seen in all of the following except:",
      "choices": [
        {
          "id": 1,
          "text": "Antiphospholipid antibody syndrome"
        },
        {
          "id": 2,
          "text": "Vasculitis"
        },
        {
          "id": 3,
          "text": "Prosthetic heart valves"
        },
        {
          "id": 4,
          "text": "Eclampsia"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Microangiopathic&nbsp;hemolytic anemia (MAHA) is not seen in <strong>prosthetic</strong> <strong>heart</strong> <strong>valves</strong>. It is associated with <strong>macroangiopathic</strong> hemolytic anemia.</p>\n<p><strong>MAHA</strong> refers to cell fragmentation that occurs in <strong>microcirculation</strong>. Microvascular lesions lead to luminal narrowing due to the deposition of fibrin and platelets. These produce shear stress that mechanically injures passing red cells. Hence, it is a type of non-immune hemolysis (<strong>Coombs-negative</strong>). On peripheral blood smear, <strong>schistocytes</strong> are seen.</p>\n<p>Common causes of MAHA include:</p>\n<ul>\n<li>Thrombotic thrombocytopenic purpura</li>\n<li>Hemolytic uremic syndrome</li>\n<li>Disseminated intravascular coagulation</li>\n<li><strong>Vasculitis</strong></li>\n<li>Malignant hypertension</li>\n<li><strong>APLA</strong> syndrome</li>\n<li>Drug-induced hemolysis</li>\n<li><strong>Eclampsia</strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4354",
      "difficulty": "medium"
    },
    {
      "text": "In patients with atypical hemolytic uremic syndrome, which of the following mutations is associated with the best prognosis?",
      "choices": [
        {
          "id": 1,
          "text": "Complement factor H"
        },
        {
          "id": 2,
          "text": "Complement factor I"
        },
        {
          "id": 3,
          "text": "Complement factor B"
        },
        {
          "id": 4,
          "text": "Membrane cofactor protein"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The <strong>best prognosis</strong> in atypical HUS is seen in <strong>membrane cofactor protein</strong> (MCP) gene&nbsp;mutation.</p>\n<p>Familial HUS or atypical HUS (aHUS) is the only inherited cause of extracorpuscular&nbsp;hemolytic anemia.&nbsp;It can occur due to <strong>mutations</strong> in any one of several genes encoding <strong>complement regulatory proteins</strong>. Mutations&nbsp;in the following genes are seen:</p>\n<ul>\n<li>Membrane cofactor protein - best&nbsp;prognosis</li>\n<li>Complement factor B -&nbsp;worst prognosis&nbsp;</li>\n<li>Complement factor H - most common&nbsp;</li>\n<li>Complement factor I - least common&nbsp;</li>\n</ul>\n<p>In these patients, infection or other triggers cause complement activation through the alternative pathway. This causes hemolysis and damage to endothelial cells in the kidney. It is usually self-limited.</p>\n<p>The standard treatment is <strong>plasma exchange</strong>. Eculizumab has recently been shown to be beneficial in atypical HUS.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4355",
      "difficulty": "hard"
    },
    {
      "text": "You have decided to prescribe an oral iron chelator for a 10-year-old girl with thalassemia. Which of the following will you not prefer?",
      "choices": [
        {
          "id": 1,
          "text": "Deferiprone"
        },
        {
          "id": 2,
          "text": "Deferasirox"
        },
        {
          "id": 3,
          "text": "Deferoxamine"
        },
        {
          "id": 4,
          "text": "Both A and B"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Deferoxamine</strong> has poor oral bioavailability and is administered <strong>parenterally</strong> (SC/IV).</p>\n<p>Oral formulations of both<strong>&nbsp;deferiprone</strong> and <strong>d</strong><strong>eferasirox</strong> are available.</p>\n<p><span class=\"nowrap\">The adverse effects of iron chelators include:</span></p>\n<ul>\n<li><span class=\"nowrap\">Deferiprone -&nbsp;neutropenia, and agranulocytosis.</span></li>\n<li><span class=\"nowrap\">Deferasirox - transaminitis and mild, asymptomatic rise in serum creatinine</span></li>\n<li><span class=\"nowrap\">Deferoxamine - occasional cataracts, deafness, and local skin reactions, but is usually well-tolerated</span></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0840",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is the best test to screen patients for thalassemia?",
      "choices": [
        {
          "id": 1,
          "text": "Cellulose acetate hemoglobin electrophoresis"
        },
        {
          "id": 2,
          "text": "Naked eye single tube red-cell osmotic fragility test"
        },
        {
          "id": 3,
          "text": "Eosin 5' maleimide flow cytometry"
        },
        {
          "id": 4,
          "text": "Automated high performance liquid chromatography"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Naked eye single tube red-cell osmotic fragility test (<strong>NESTROFT</strong>) is the <strong>most sensitive</strong> test to detect thalassemia in the population.&nbsp;Hence, it is an effective <strong>screening test</strong>.</p>\n<p>The principle is based on the decreased osmotic fragility of red cells in thalassemia. It is performed as follows:</p>\n<ol>\n<li>Mix EDTA blood and&nbsp;<strong>0.36% buffered saline </strong>solution.</li>\n<li>Shake the tube and leave it at room temperature for 30 minutes.</li>\n<li>Shake the tube again and immediately hold the tube in front of a piece of paper with text.</li>\n</ol>\n<table>\n<tbody>\n<tr>\n<td><strong>NESTROFT</strong></td>\n<td><strong>Inference</strong></td>\n<td><strong>Reason</strong></td>\n</tr>\n<tr>\n<td>Lines visible (negative)</td>\n<td>Normal</td>\n<td>Hemolysis has occurred</td>\n</tr>\n<tr>\n<td>Lines not seen (positive)</td>\n<td>Thalassemia</td>\n<td>Stable RBC, unable to lyse</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p>The image below shows a positive NESTROF test (test tube marked as T1) as the line is not visible through the test tube. The test tube marked as C shows the control (Please note that a negative NESTROF test would show visible lines similar to the appearance of the control).</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a609c616f696497193983869d15c7671x360x604.JPEG\" alt=\"Explanation Image\"><p>&nbsp;</p>\n<p>The following tests are <strong>specific</strong> and used to confirm the diagnosis of thalassemia:</p>\n<ul>\n<li>Hemoglobin electrophoresis</li>\n<li>High-performance liquid chromatography (HPLC)</li>\n<li>Genetic testing&nbsp;</li>\n</ul>\n<p>Note: Eosin 5' maleimide (EMA)&nbsp;flow cytometry is the most specific test for the diagnosis of hereditary spherocytosis.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0835",
      "difficulty": "easy"
    },
    {
      "text": "During a master health check-up, a 25-year-old woman was found to have the following lab values. Which of the following will help in establishing a diagnosis in this patient?<div class='question-desc-html'><p>Hemoglobin - 10g/dl</p>\n<p>MCV - 75 fL</p>\n<p>MCH - 25 pg</p>\n<p>Peripheral smear - Microcytes with target cells</p>\n<p>Iron profile&nbsp;- Normal</p>\n<p>Vitamin B12 and folate levels - Normal</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Free erythorcyte protoporphyrin levels"
        },
        {
          "id": 2,
          "text": "Hemoglobin electrophoresis"
        },
        {
          "id": 3,
          "text": "Schilling test"
        },
        {
          "id": 4,
          "text": "Bone marrow biopsy"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>This clinical scenario is consistent with <strong>&beta;-thalassemia minor</strong>. The diagnosis can be established by<strong> hemoglobin electrophoresis</strong>.</p>\n<p>This condition presents with the following features:&nbsp;</p>\n<ul>\n<li>Microcytes<strong>&nbsp;</strong>(N: 80-96 fL)</li>\n<li>Hypochromic<strong>&nbsp;</strong>(N: 27-33 pg)</li>\n<li>Mild anemia</li>\n<li>Target cells<strong>&nbsp;</strong></li>\n<li>Normal iron profile&nbsp;</li>\n</ul>\n<p>Hemoglobin electrophoresis findings are as follows:</p>\n<ul>\n<li>&nbsp;&ge;4% of HbA2</li>\n<li>&nbsp;&le;5% of HbF&nbsp;</li>\n</ul><p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Thalassaemia, a disorder affecting millions around the world, demands attention and action. The International Thalassaemia Day 2023 theme &lsquo;BE AWARE.SHARE.CARE.: Strengthening Education to Bridge the Thalassaemia Care Gap,&rsquo; stresses the significance of education in providing proper care to those affected by this condition. Signifying an increased focus on quality care and better access to treatment to bridge the gap in thalassaemia care.&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:829,&quot;3&quot;:{&quot;1&quot;:0},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;11&quot;:4,&quot;12&quot;:0}\">Thalassaemia, a disorder affecting millions around the world, demands attention and action. The International Thalassaemia Day 2023 theme &lsquo;BE AWARE.SHARE.CARE.: Strengthening Education to Bridge the Thalassaemia Care Gap,&rsquo; stresses the significance of education in providing proper care to those affected by this condition. It signifies an increased focus on quality care and better access to treatment to bridge the gap in thalassaemia care.</span></p><hr><h3>Related Pearl: Differential Diagnosis of Microcytic Anaemia</h3><table>\n<tbody>\n<tr>\n<td>Investigation</td>\n<td><strong>Iron- Deficiency Anemia</strong></td>\n<td><strong>Alpha or beta thalassemia</strong></td>\n<td><strong>Anemia of Chronic Disease</strong></td>\n</tr>\n<tr>\n<td><strong>Serum Iron</strong></td>\n<td>&lt;60 &micro;g/dL</td>\n<td>Normal/Increased</td>\n<td>Decreased</td>\n</tr>\n<tr>\n<td><strong>Serum Ferritin</strong></td>\n<td>&lt;20 &micro;g/L</td>\n<td>Normal/Increased</td>\n<td>Increased</td>\n</tr>\n<tr>\n<td><strong>TIBC</strong></td>\n<td>Increased</td>\n<td>Normal</td>\n<td>Decreased</td>\n</tr>\n<tr>\n<td><strong>Transferrin saturation</strong></td>\n<td>&lt;15%</td>\n<td>Normal</td>\n<td>Normal/Decreased</td>\n</tr>\n<tr>\n<td><strong>MCV</strong></td>\n<td>Decreased</td>\n<td>&nbsp;Decreased</td>\n<td>Normal/Decreased</td>\n</tr>\n<tr>\n<td><strong>RBC count</strong></td>\n<td>Decreased</td>\n<td>Normal/Increased</td>\n<td>Normal/Increased</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>TIBC: Total iron-binding capacity&nbsp;</p><hr><h3>Related Pearl: Thalassemia syndromes</h3><p>Normally each individual carries 4 functional alpha chain genes and 2 functional beta chain genes. Alpha and beta-thalassemia are inherited disorders in which there is reduced production of alpha-globin or beta-globin chains, respectively.</p>\n<ul>\n<li data-canvas-width=\"535.628896311106\"><strong>Alpha thalassemia:</strong> Gene deletion is the most common cause of reduced α-chain synthesis.</li>\n<li data-canvas-width=\"535.628896311106\"><strong>Beta +- thalassemia:</strong> The most common cause is splicing mutation.</li>\n<li data-canvas-width=\"535.628896311106\"><strong>Beta 0- thalassemia:</strong> Chain terminator mutations are the most common cause.</li>\n</ul>\n<p>The table below describes the features of typical thalassemia syndromes:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Alpha thalassemias</strong></td>\n<td><strong> Hb Barts</strong></td>\n<td><strong>HbH disease </strong></td>\n<td><strong>Minor</strong></td>\n<td><strong>Silent carrier</strong></td>\n</tr>\n<tr>\n<td><strong>Genotype</strong></td>\n<td>(- - / - - )</td>\n<td>\n<p>(α -/ - -)</p>\n<p>or</p>\n<p>(α<span>*</span> -/ - -)</p>\n</td>\n<td>\n<p>(α -/α -)</p>\n<p>or</p>\n<p>(α α/- -)</p>\n</td>\n<td>(α α/α -)</td>\n</tr>\n<tr>\n<td><strong>Laboratory findings</strong></td>\n<td>Severe microcytic anemia with hydrops fetalis; fatal in utero</td>\n<td>Moderate microcytic anemia</td>\n<td>Mild microcytic anemia</td>\n<td>Normal hemoglobin, normal MCV</td>\n</tr>\n<tr>\n<td><strong>Hemoglobin electro-phoresis</strong></td>\n<td>Hb Barts (γ globin tetramers); Hb Portland (embryonic hemoglobin); no HbF, HbA, or HbA<sub>2</sub></td>\n<td>HbH (beta-globin tetramers -up to 30%); HbA<sub>2 </sub>(up to 4%)</td>\n<td>Hb Barts (3 to 8%)</td>\n<td>Normal</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>\"-\" denotes deletion of an alpha gene and \"α\" denotes normal alpha gene and \"α* \" refers to a mutant alpha chain gene.</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Beta thalassemias</strong></td>\n<td><strong>Major (transfusion-dependent)</strong></td>\n<td><strong>Intermedia (non-transfusion-dependent)</strong></td>\n<td><strong>Minor (also called trait or carrier)</strong></td>\n</tr>\n<tr>\n<td><strong>Genotype</strong></td>\n<td>\n<p>Homozygous</p>\n<p>β<sup>0</sup>/β<sup>0</sup></p>\n<p>or</p>\n<p>β<sup>0</sup>/β<sup>+</sup></p>\n<p>or</p>\n<p>β+/β+ </p>\n</td>\n<td>\n<p>Variable</p>\n<p>β0/β+</p>\n<p>or</p>\n<p>β<sup>+</sup>/β<sup>+</sup></p>\n<p>or</p>\n<p>β0/β</p>\n<p>or</p>\n<p>β+/β</p>\n</td>\n<td>\n<p>Heterozygous</p>\n<p>β<sup>0</sup>/β</p>\n<p>or</p>\n<p>β<sup>+</sup>/β</p>\n</td>\n</tr>\n<tr>\n<td><strong>Laboratory findings</strong></td>\n<td>Severe microcytic anemia with target cells (typical Hb 3 to 4 g/dL)</td>\n<td>Moderate microcytic anemia</td>\n<td>Mild microcytic anemia</td>\n</tr>\n<tr>\n<td><strong>Hemoglobin electrophoresis</strong></td>\n<td>HbA<sub>2 </sub>(5% or more); HbF (up to 95%); no HbA</td>\n<td>HbA<sub>2</sub> (4% or more); HbF (up to 50%)</td>\n<td>HbA<sub>2</sub> (4% or more); HbF (up to 5%)</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>β<sup>0</sup> refers to no beta-globin production; β<sup>+</sup> refers to decreased beta-globin production.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4365",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following clinical manifestations is not associated with sickle cell trait?",
      "choices": [
        {
          "id": 1,
          "text": "Hyposthenuria "
        },
        {
          "id": 2,
          "text": "Painless hematuria"
        },
        {
          "id": 3,
          "text": "Papillary necrosis"
        },
        {
          "id": 4,
          "text": "Acute pain crisis"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Acute pain crisis</strong> is <strong>not associated</strong> with <strong>sickle cell trait</strong>. Acute pain crisis is classicaly seen in sickle cell disease.&nbsp;</p>\n<p>Manifestations of sickle cell trait include:</p>\n<ul>\n<li>Often <strong>asymptomatic</strong>.</li>\n<li><strong>Hyposthenuria</strong></li>\n<li><strong>Painless hematuria</strong> - due to <strong>papillary necrosis</strong></li>\n<li>Recurrent UTIs</li>\n<li>Risk of renal medullary carcinoma - rare</li>\n<li>Increased risk of CKD</li>\n<li>Sloughing of papillae with urethral obstruction is very rare</li>\n<li>Anemia and painful crises are rare.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0845",
      "difficulty": "hard"
    },
    {
      "text": "Patients with sickle cell anemia most commonly present with which of the following?",
      "choices": [
        {
          "id": 1,
          "text": "Acute pain crisis"
        },
        {
          "id": 2,
          "text": "Splenic sequestration crisis"
        },
        {
          "id": 3,
          "text": "Acute chest syndrome"
        },
        {
          "id": 4,
          "text": "Isosthenuria"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Acute pain crisis</strong> is the most common clinical presentation of<strong> sickle cell anemia</strong>.</p>\n<p>These are intermittent episodes of<strong>&nbsp;vaso-occlusion</strong>&nbsp;in connective and musculoskeletal structures. This results in ischemia resulting in acute pain and tenderness, fever, tachycardia, and anxiety.&nbsp;The management includes vigorous hydration, evaluation for underlying causes, and aggressive analgesia.</p>\n<p>Other manifestations of sickle cell anemia include:</p>\n<ul>\n<li><strong>Hand-foot</strong> syndrome - painful infarcts of the digits and dactylitis</li>\n<li><strong>Priapism</strong> - infarction of the penile venous outflow tracts</li>\n<li>Chronic lower leg ulcers - ischemia and superinfection in the distal circulation</li>\n<li><strong>Splenic sequestration </strong>crisis&nbsp;<strong>-</strong>&nbsp;life-threatening&nbsp;complication due to acute venous obstruction that requires emergency transfusion and/or splenectomy</li>\n<li><strong>Aplastic crisis</strong> - commonly secondary to parvovirus B19 infection</li>\n<li><strong>Acute chest syndrome</strong>&nbsp;- sickling within the lung, producing pain and temporary pulmonary dysfunction. Treatment&nbsp;may include lifelong transfusion support, using partial exchange transfusion</li>\n<li><strong>Stroke</strong> - common in children</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0842",
      "difficulty": "medium"
    }
  ]
}